Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.33 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Takeda Provides Update on EXKIVITY® (mobocertinib)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So.
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that... 
Via Benzinga
Topics Economy
Exposures Economy
Looking Into Takeda Pharmaceutical's Recent Short Interest
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are attractive buys right now. 
Via The Motley Fool
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
How Is The Market Feeling About Takeda Pharmaceutical?
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
Via Benzinga
Morphic Therapeutic's Stock Plunges On Monday - Here's Why?
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days
The company is working on a treatment for ulcerative colitis. But competitive questions linger. 
Via Investor's Business Daily
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
Top 4 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Is This 250-Year-Old Japanese Big Pharma Giant Selling For Half Price Right Now?
When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to... 
Via Benzinga
Ovarian Cancer Player ImmunoGen Can Potentially Be Attractive M&A Target: JP Morgan
JP Morgan upgraded ImmunoGen Inc (NASDAQ: IMGN) from Neutral to Overweight with a price target of $22, up from $9, based on insights gathered from a recent physician survey, which focused on the... 
Via Benzinga
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
From Takeda Pharmaceutical Company Limited
Via Business Wire
ImmunoGen Inks Pact With Takeda To Develop ELAHERE Ovarian Cancer Drug In Japan
ImmunoGen, Inc. (NASDAQ: IMGN) inked pacts with Takeda Pharmaceutical Company Limited (NYSE: TAK) to develop and  
Via Benzinga
Why Are Poseida Therapeutics Shares Moving Higher Today?
Poseida Therapeutics Inc (NASDAQ: PSTX) shares are trading higher after the company received a $50 million strategic investment by Astellas Pharma Inc (OTC: ALMPY) (OTC: 
Via Benzinga
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
From Takeda Pharmaceutical Company Limited
Via Business Wire
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
From Takeda Pharmaceutical Company Limited
Via Business Wire
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories
Wall Street Journal 
Via Benzinga
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily  
Via Benzinga
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.